- ►viamedica.pl [PDF] P Vague, JL Selam, S Skeie, I De Leeuw, JWF Elte, … - Diabetes Care, 2003 - Am Diabetes Assoc 1 Hôpital de la Timone, Service Nutrition Endocrinologie et Maladies Metabolique,
Marseilles, France 2 Hotel Dieu, Service de Diabétologie, Paris, France 3 Hjertelaget Research
Foundation, Stavanger, Norway 4 Department of Endocrinology, University of Antwerp, ... Cited by 234 - Related articles - BL Direct - All 8 versions
- ►pr-ide.be [PDF] K Hermansen, P Fontaine, KK Kukolja, V Peterkova, G … - Diabetologia, 2004 - Springer Aims/hypothesis. The aim of the trial was to compare the efficacy and tolerability of two types
of basal-bolus therapy, using either the soluble long-acting basal insu- lin analogue, insulin
detemir, in combination with the rapid-acting analogue, insulin aspart, or NPH insulin in ... Cited by 231 - Related articles - BL Direct - All 10 versions
P Home, P Bartley, D Russell-Jones, H Hanaire- … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—With both insulin detemir groups, clinic fasting plasma glucose was lower than with
NPH insulin (IDet 12h vs. NPH, −1.5 mmol/l [95% CI −2.51 to −0.48], P = 0.004; IDet morn+bed
vs. NPH, −2.3 mmol/l (−3.32 to −1.29), P < 0.001), as was self-measured prebreakfast ... Cited by 153 - Related articles - BL Direct - All 7 versions
E Standl, H Lang, A Roberts - Diabetes technology & therapeutics, 2004 - liebertonline.com EBERHARD STANDL, MD,1 HANNE LANG, M.Sc.,2 and ANTHONY ROBERTS, MD3 ...
Background: This trial compared the long-term safety and efficacy of the basal insulin prepa-
rations, insulin detemir and NPH insulin, in basal-bolus therapy for patients with type 1 ... Cited by 85 - Related articles - BL Direct - All 3 versions
I De Leeuw, P Vague, JL Selam, S Skeie, … - Diabetes Obesity …, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 130 - Related articles - All 5 versions
D Russell-Jones, R Simpson, B Hylleberg, E Draeger, J … - Clinical therapeutics, 2004 - Elsevier Methods: This was a 6-month, prospective, randomized, open-label, controlled, parallel-group
trial conducted at 92 sites in Europe and Australia. The trial population included men and women
with type 1 DM for at least 1 year aged ≥ 18 years with glycosylated hemoglobin (HbA 1c ... Cited by 122 - Related articles - All 4 versions
- ►diabetesjournals.org K Hermansen, S Madsbad, H Perrild, A Kristensen, … - Diabetes Care, 2001 - Am Diabetes Assoc OBJECTIVE— Insulin detemir (NN304) is a soluble basal insulin analog developed to cover
basal insulin requirements. This trial aimed to compare the blood glucose—lowering effect of
insulin detemir with that of NPH insulin (NPH) and to evaluate the two treatments with ... Cited by 147 - Related articles - BL Direct - All 7 versions
T Heise, L Nosek, BB Rønn, L Endahl, L Heinemann, C … - Diabetes, 2004 - Am Diabetes Assoc The aim of this randomized double-blind study was to compare the within-subject variability of
the glucose-lowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine
and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 ... Cited by 293 - Related articles - BL Direct - All 13 versions
T Haak, A Tiengo, E Draeger, M Suntum, W … - Diabetes Obesity and …, 2005 - fe-inzichten.nl Aim: The aim of this study was to compare the efficacy and safety of a basal-bolus insulin regimen
comprising either insulin detemir or neural protamine hagedorn (NPH) insulin in combination
with mealtime insulin aspart in patients with type 2 diabetes. Methods: This was a ... Cited by 193 - Related articles - View as HTML - All 5 versions
TR Pieber, E Draeger, A Kristensen, V Grill - Diabetic Medicine, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 89 - Related articles - All 4 versions
